Publication at Third Faculty of Medicine |
2004
Abstract
Adefovir dipivoxil is a new nucleotide analog derived from adenosin-monophosphate. At the 10mg/day dose significantly decreases HBV DNA in serum, activity of transaminases, and leads to better histology results in liver assessment of adults with hepatitis B in the phase of active viral replication.
Treatment with Adefovir dipivoxil is a long term treatment (48 weeks), it is well tolerated, and side effects are moderate and reversible. It can be administered to HBeAg positive patients, to patients with HBV mutant unable to create HBeAg if positive HBV DNA in serum, and to patients with lamivudine resistant HBV mutant